Clinical trial is the main gateway for the drug to hit the public market. The clinical trials now bring the new drug Mekena to treat the premature births in the women. The women that give the birth to the premature baby will have the risk of reoccurance when compared to the women who delivers developed baby. FDA approved Mekena is designed to treat the risk factor the women that give the birth to premature babies.
The clinical trial conducted with the group of 463 women with singleton pregnancies and gave the positive results. The Mekena treated women experienced the drastic increase in their time period of delivery when compared to the patients that received the placebo.
No comments:
Post a Comment